日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Evaluating the clinical utility of ctDNA testing to identify molecular cancer progression - lessons from SERENA-6

评估ctDNA检测在识别分子癌症进展方面的临床应用价值——来自SERENA-6的经验教训

Taranto, Eleanor; DeMichele, Angela

Identification of Early Symptoms Associated with Subsequent Immune-related Adverse Events in the I-SPY clinical trial

在 I-SPY 临床试验中识别与后续免疫相关不良事件相关的早期症状

Basu, Amrita; Umashankar, Saumya; Melisko, Michelle; Roy, Ritu; Yau, Christina; Pusztai, Lajos; Chien, A Jo; Liu, Minetta; Han, Hyo; Soliman, Hatem; Isaacs, Claudine; Shatsky, Rebecca; Stringer-Reasor, Erica; Robinson, Patricia; Yeung, Kay; Kalinsky, Kevin; Thomas, Alexandra; Philip, Errol; Musthafa, Mina; Hirst, Gillian; Asare, Adam; DeMichele, Angela; Van't Veer, Laura; Yee, Douglas; Hylton, Nola; Olshen, Adam; Perlmutter, Jane; Cohen, Ronald N; Quandt, Zoe; Esserman, Laura; Hershman, Dawn; Rugo, Hope; Nanda, Rita

Pathologic complete response (pCR) rates for patients with HR+/HER2- high-risk, early-stage breast cancer (EBC) by clinical and molecular features in the phase II I-SPY2 clinical trial

在 II 期 I-SPY2 临床试验中,根据临床和分子特征分析 HR+/HER2- 高危早期乳腺癌 (EBC) 患者的病理完全缓解 (pCR) 率

Huppert, L A; Wolf, D; Yau, C; Brown-Swigart, L; Hirst, G L; Isaacs, C; Pusztai, L; Pohlmann, P R; DeMichele, A; Shatsky, R; Yee, D; Thomas, A; Nanda, R; Perlmutter, J; Heditsian, D; Hylton, N; Symmans, F; Van't Veer, L J; Esserman, L; Rugo, H S

Circulating tumor DNA refines risk stratification of neoadjuvant therapy-resistant breast tumors

循环肿瘤DNA可优化新辅助治疗耐药性乳腺肿瘤的风险分层

Magbanua, Mark Jesus M; Manon, Nayelis A; Wolf, Denise M; Rivero-Hinojosa, Samuel; Ahmed, Ziad; Sayaman, Rosalyn W; Tin, Antony; Renner, Derrick; Kalashnikova, Ekaterina; Brown-Swigart, Lamorna; Hirst, Gillian L; Yau, Christina; Li, Wen; Isaacs, Claudine; Shatsky, Rebecca A; Clark, Amy S; Zimmer, Alexandra; Delson, Amy L; Rodriguez, Angel; Liu, Minetta C; Pohlmann, Paula R; Esserman, Laura J; Rugo, Hope S; DeMichele, Angela; van 't Veer, Laura

Phase II Study of Palbociclib in Patients with Tumors with CDK4 or CDK6 Amplification: Results from the NCI-MATCH ECOG-ACRIN Trial (EAY131) Subprotocol Z1C

帕博西尼治疗 CDK4 或 CDK6 扩增肿瘤患者的 II 期研究:NCI-MATCH ECOG-ACRIN 试验 (EAY131) 子方案 Z1C 的结果

O'Hara, Mark H; Jegede, Opeyemi; Dickson, Mark A; DeMichele, Angela M; Piekarz, Richard; Gray, Robert J; Wang, Victoria; McShane, Lisa M; Rubinstein, Lawrence V; Patton, David R; Williams, P Mickey; Hamilton, Stanley R; Onitilo, Adedayo; Tricoli, James V; Conley, Barbara A; Arteaga, Carlos L; Harris, Lyndsay N; O'Dwyer, Peter J; Chen, Alice P; Flaherty, Keith T

Drug-drug interactions between palbociclib and proton pump inhibitors in early breast cancer: an exploratory analysis of PALLAS (ABCSG-42/AFT-05/BIG-14-13/PrE0109)

帕博西尼与质子泵抑制剂在早期乳腺癌中的药物相互作用:PALLAS(ABCSG-42/AFT-05/BIG-14-13/PrE0109)探索性分析

Agostinetto, E; Pfeiler, G; Hlauschek, D; Mayer, E L; Lambertini, M; de Azambuja, E; Bellet-Ezquerra, M; Meisel, J L; Rubovszky, G; Zdenkowski, N; Novik, Y; Ruiz-Borrego, M; Gelmon, K A; Mamounas, E P; Iwata, H; Lu, D R; Soelkner, L; Fesl, C; Gnant, M; DeMichele, A

Quality-of-life and symptom severity in the PALLAS randomized trial of palbociclib with adjuvant endocrine therapy in early breast cancer (AFT-05, ABCSG-42, BIG-14-03, PrE0109)

在早期乳腺癌患者中,帕博西尼联合辅助内分泌治疗的 PALLAS 随机试验中的生活质量和症状严重程度(AFT-05、ABCSG-42、BIG-14-03、PrE0109)

Naughton, M J; Zahrieh, D M; Gnant, M; Zdenkowski, N; Lemieux, J; Mao, J J; Bjelic-Radisic, V; Shinn, E; Balic, M; Thomssen, C; Meisel, J L; Ruiz, G M; Loibl, S; Isaacs, C; Cameron, D; Henao-Carrasco, F M; Goetz, M P; Singer, C F; Werutsky, G; Rugo, H S; Vetter, M; Tseng, L-M; Miller, K; Fitzal, F; Gil Gil, J M; Park, H; Linderholm, B; Bajetta, E; Dayao, Z; Prat, A; Ehrhardt, K; Metzger, O; Arahmani, A; Law, E H; Partridge, A H; Carey, L A; Zoroufy, A; Dueck, A C; O'Brien, P; Hlauschek, D; DeMichele, A; Mayer, E L

Circulating tumor DNA mutational landscape and dynamics after progression on a CDK4/6 inhibitor in the PACE phase II trial for metastatic HR-positive/HER2-negative breast cancer

在 PACE II 期临床试验中,转移性 HR 阳性/HER2 阴性乳腺癌患者接受 CDK4/6 抑制剂治疗后,循环肿瘤 DNA 突变图谱和动态变化

Jeselsohn, R; Fu, J; Ren, Y; Mahtani, R; Ma, C; DeMichele, A; Cristofanilli, M; Meisel, J; Miller, K D; Abdou, Y; Riley, E C; Qamar, R; Sharma, P; Reid, S; Ko, N; Liu, Y; Gauthier, E; Burstein, H J; DeMeo, M; Regan, M; Tolaney, S M; Mayer, E L

A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer

一项汇总分析评估了残余癌负荷在浸润性小叶乳腺癌中的预后意义

Mukhtar, Rita A; Gottipati, Soumya; Yau, Christina; López-Tarruella, Sara; Earl, Helena; Hayward, Larry; Hiller, Louise; Osdoit, Marie; van der Noordaa, Marieke; de Croze, Diane; Hamy, Anne-Sophie; Laé, Marick; Reyal, Fabien; Sonke, Gabe S; Steenbruggen, Tessa G; van Seijen, Maartje; Wesseling, Jelle; Martín, Miguel; Del Monte-Millán, Maria; Boughey, Judy C; Goetz, Matthew P; Hoskin, Tanya; Valero, Vicente; Edge, Stephen B; Abraham, Jean E; Bartlett, John M S; Caldas, Carlos; Dunn, Janet; Provenzano, Elena; Sammut, Stephen-John; Thomas, Jeremy S; Graham, Ashley; Hall, Peter; Mackintosh, Lorna; Fan, Fang; Godwin, Andrew K; Schwensen, Kelsey; Sharma, Priyanka; DeMichele, Angela M; Cole, Kimberly; Pusztai, Lajos; Kim, Mi-Ok; J van 't Veer, Laura; Cameron, David; Esserman, Laura J; Fraser Symmans, W

CHFR expression and sensitivity of breast cancer cells to antimitotic agents in vitro and in the I-SPY trial

CHFR表达及乳腺癌细胞对体外和I-SPY试验中抗有丝分裂药物的敏感性

Wahner Hendrickson, Andrea E; Flatten, Karen S; Weiskittel, Taylor M; Venkatachalam, Annapoorna; Strathman, Annabella R; Rossman, Olivia K; Meng, X Wei; Schneider, Paula A; Peterson, Kevin L; Correia, Cristina; Anderson, Olivia J; Singh, Saloni; Couch, Fergus J; Esserman, Laura J; Hylton, Nola M; Onishi, Natsuko; DeMichele, Angela M; Chen, Junjie; Li, Hu; Ingle, James N; Goetz, Matthew P; Kaufmann, Scott H